Non-invasive monitoring of anticancer effects of cisplatin on lung cancer in an orthotopic SCID mouse model using [18F] FDG PET-CT
Non-invasive monitoring of anticancer effects of cisplatin on lung cancer in an orthotopic SCID mouse model using [18F] FDG PET-CT
复制标题
DOI：
10.3892/or.2014.3056
复制
发表时间：
2014-05-01
期刊：
影响因子：
4.2
通讯作者：
Tangoku, Akira
中科院分区：
文献类型：
--
作者：
Mokhtar, Mohamed;Kondo, Kazuya;Tangoku, Akira
正电子发射断层扫描-计算机断层扫描（PET-CT）与[F-18]氟脱氧葡萄糖（FDG）最近已被应用于评估肿瘤对抗癌治疗的反应。本研究的目的是评估FDG PET-CT在监测顺铂（CDDP）对原位肺癌模型的抑制作用中的无创性和重复性的实用性。在原位SCID小鼠模型中进行人肺癌Ma 44 -3细胞系中的体内FDG摄取的验证。接下来，我们评估了FDG PET-CT用于监测原位肺癌对CDDP抗癌作用的反应。将SCID小鼠分为CDDP组（7 mg/kg单次腹腔注射）和对照组。计算所有小鼠的肿瘤体积和最大标准化摄取值（SUV max）。处死所有小鼠进行组织病理学分析。FDG PET-CT的验证显示肿瘤体积和SUV max分别与标本中测量的死后肿瘤长度显著相关（P=0.023）和（P=0.012），并且SUV max与肿瘤体积显著相关（P=0.048）。反应监测显示，CDDP组以SUV max形式的显著生长抑制在第8天（P=0.02）和第13天（P=0.003）显著低于对照组。CDDP组肿瘤体积在第13天显著低于对照组（P=0.03）。本研究支持在原位模型中使用FDG PET-CT无创和重复地监测肺癌的肿瘤进展和治疗反应。
Positron emission tomography-computed tomography (PET-CT) with [F-18] fluorodeoxyglucose (FDG) has recently been applied for evaluating tumor response to anticancer therapy. The aim of the present study was to evaluate the utility of FDG PET-CT in monitoring non-invasively and repeatedly the inhibitory effect of cisplatin (CDDP) on an orthotopic lung cancer model. Validation of in vivo FDG uptake in human lung cancer Ma44-3 cell line in an orthotopic SCID mouse model was carried out. Next, we assessed the use of FDG PET-CT to monitor the response of orthotopic lung cancer to the anticancer effect of CDDP. SCID mice were divided into the CDDP group (7 mg/kg single dose intraperitoneally) and the control group. Tumor volume and maximal standardized uptake value (SUV max) were calculated for all mice. All mice were sacrificed for histopathologic analysis. Validation of FDG PET-CT showed that tumor volume and SUV max were significantly correlated with postmortem tumor length measured in specimens (P=0.023) and (P=0.012), respectively, and there was a significant correlation between SUV max and tumor volume (P=0.048). Response monitoring showed that significant growth inhibition by CDDP in the form of SUV max of the CDDP group was significantly lower than that of the control group on day 8 (P=0.02) and on day 13 (P=0.003). Tumor volume of the CDDP group was significantly lower than that of the control group on day 13 (P=0.03). The present study supports using FDG PET-CT in monitoring tumor progression and therapeutic response of lung cancer in an orthotopic model non-invasively and repeatedly.